BSX Quote, Financials, Valuation and Earnings

Haemonetics has a net margin of 12.41% compared to Boston Scientific's net margin of 10.76%. Boston Scientific's return on equity of 8.96% beat Haemonetics's return on equity of 14.16%.

Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 21.23%. On the other hand Haemonetics has an analysts' consensus of $96.80 which suggests that it could grow by 46.82%. Given that Haemonetics has higher upside potential than Boston Scientific, analysts believe Haemonetics is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.430, suggesting its less volatile than the S&P 500 by 57.014%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.6B, which are larger than Haemonetics quarterly revenues of $348.5M. Boston Scientific's net income of $566M is higher than Haemonetics's net income of $37.5M. Notably, Boston Scientific's price-to-earnings ratio is 76.30x while Haemonetics's PE ratio is 25.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 2.46x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 12.41% compared to Boston Scientific's net margin of 15.24%. Boston Scientific's return on equity of 8.96% beat Johnson & Johnson's return on equity of 19.98%.

Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 21.23%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.73%. Given that Boston Scientific has higher upside potential than Johnson & Johnson, analysts believe Boston Scientific is more attractive than Johnson & Johnson.

Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.04% to investors and pays a quarterly dividend of $1.24 per share. Boston Scientific pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.6B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Boston Scientific's net income of $566M is lower than Johnson & Johnson's net income of $3.4B. Notably, Boston Scientific's price-to-earnings ratio is 76.30x while Johnson & Johnson's PE ratio is 28.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 12.41% compared to Boston Scientific's net margin of 26.88%. Boston Scientific's return on equity of 8.96% beat ResMed's return on equity of 25.56%.

Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 21.23%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 22.6%. Given that ResMed has higher upside potential than Boston Scientific, analysts believe ResMed is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. Boston Scientific pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.6B, which are larger than ResMed quarterly revenues of $1.3B. Boston Scientific's net income of $566M is higher than ResMed's net income of $344.6M. Notably, Boston Scientific's price-to-earnings ratio is 76.30x while ResMed's PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 6.58x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 12.41% compared to Boston Scientific's net margin of 8.48%. Boston Scientific's return on equity of 8.96% beat Stryker's return on equity of 15.22%.

Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 21.23%. On the other hand Stryker has an analysts' consensus of $424.43 which suggests that it could grow by 16.71%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Stryker has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.393%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.89% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.6B, which are smaller than Stryker quarterly revenues of $6.4B. Boston Scientific's net income of $566M is higher than Stryker's net income of $546M. Notably, Boston Scientific's price-to-earnings ratio is 76.30x while Stryker's PE ratio is 46.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.46x versus 6.21x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.